A new campaign has been launched by Virbac to highlight the benefits of Cortavance, its topical corticosteroid spray for the treatment of pruritic dermatoses in dogs.
The campaign – themed “The art of skin treatment” – aims to remind veterinary staff to consider topical, non-systemic therapies for the treatment of certain pruritic skin conditions.
Virbac product manager Vicky Standen, said: “Treating a skin condition is an art form in itself. Each case is different and monitoring recovery, and the management of flare ups forms part of the long-term care plan that should be considered when choosing the most effective product for the pet – and the owner.
“Cortavance has proved popular since its launch seven years ago but we wanted to remind vets that it is not only a solution for ‘hot spots’ and that its speed of action and excellent acceptance make it a useful addition to the range of therapeutic options for the treatment of skin conditions.”
Cortavance contains HCA (hydrocortisone aceponate) – the first specific dermocorticoid (a glucocorticosteroid which acts only on the skin) to be used in veterinary medicine – which studies show is up to 60 times more potent than hydrocortisone.
According to Virbac, as the product only acts in the skin, there is no transdermal absorption at dose level and Cortavance has no known incompatibilities or side effects so can be used either as a monotherapy or in conjunction with other medication.
Paul Sands, partner at Pride Veterinary Centre in Derby, said: “I use Cortavance in patients with pruritic inflamed skin where infection is not a major component. I have found it particularly effective in treating the insides of ear flaps, feet and on abdomens/axillae. It is highly efficacious with a rapid onset of effect and lack of systemic effects which, I believe, makes it safer for patients.”